` URGN (Urogen Pharma Ltd) vs S&P 500 Comparison - Alpha Spread

URGN
vs
S&P 500

Over the past 12 months, URGN has underperformed S&P 500, delivering a return of +16% compared to the S&P 500's +17% growth.

Stocks Performance
URGN vs S&P 500

Loading
URGN
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
URGN vs S&P 500

Loading
URGN
S&P 500
Difference
www.alphaspread.com

Performance By Year
URGN vs S&P 500

Loading
URGN
S&P 500
Add Stock

Competitors Performance
Urogen Pharma Ltd vs Peers

S&P 500
URGN
ABBV
CYTH
AMGN
GILD
Add Stock

Urogen Pharma Ltd
Glance View

Market Cap
800.7m USD
Industry
Biotechnology

UroGen Pharma Ltd. is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases. The firm is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).

URGN Intrinsic Value
27.88 USD
Undervaluation 32%
Intrinsic Value
Price
Back to Top